摘要
目的:评价前列地尔在造血干细胞移植中预防肝静脉闭塞病(hepaticveno-occlusivedisease,HVOD)的作用。方法:将80例次造血干细胞移植的患者分成两组,其中研究组45例次用前列地尔(每次20μg静脉滴注,每日2次,移植前8日至移植后28日使用)预防HVOD,对照组35例次则未采用预防措施。比较两组HVOD的发生率。结果:研究组未发生HVOD,对照组4例发生严重HVOD,均导致死亡。两组HVOD发生率比较有统计学意义(P<0.05)。结论:前列地尔在造血干细胞移植中预防HVOD效果好,安全可靠。
Objective: To evaluate the effect of alprostadil for the prevention of hepatic veno occlusive disease (HVOD) after hematopoietic stem cell transplantation. Methods: The clinic data of 45 cases who accepted administration of alprostadil (treat with 20 μ g alprostadil, twice daily injection of vein) were analyzed and the incidence of HVOD was compared with 35 cases who didn't accept alprostadil in the same period. Results: No HVOD occurred in the patients who acceptd alprostadil, and 4 patients who didn't accept alprostadil died from severe HVOD. Conclusion: Alprostadil is a safe and effective drug for the prevention of HVOD after hematopoietic stem cell transplantation.
出处
《新医学》
北大核心
2003年第5期296-297,共2页
Journal of New Medicine
关键词
前列地尔
造血干细胞移植
肝静脉闭塞病
预防
发生率
Hepatic veno occlusive disease Hematopoietic stem cell transplantation Alprostadil Prevention Incidence
